9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients

Julian Stumpf; Leona Anders; Torsten Siepmann; Jörg Schwöbel; Claudia Karger; Tom Lindner; Robert Faulhaber-Walter; Torsten Langer; Katja Escher; Kirsten Anding-Rost; Harald Seidel; Jan Hüther; Frank Pistrosch; Heike Martin; Jens Schewe; Thomas Stehr; Frank Meistring; Alexander Paliege; Daniel Schneider; Ingolf Bast; Anne Steglich; Florian Gembardt; Friederike Kessel; Hannah Kröger; Patrick Arndt; Jan Sradnick; Kerstin Frank; Sarah Skrzypczyk; Moritz Anft; Anna Klimova; René Mauer; Ingo Roeder; Torsten Tonn; Nina Babel; Christian Hugo

doi:10.1016/j.vaccine.2023.12.034

9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients

Julian Stumpf, Leona Anders, Torsten Siepmann, Jörg Schwöbel, Claudia Karger, Tom Lindner, Robert Faulhaber-Walter, Torsten Langer, Katja Escher, Kirsten Anding-Rost, Harald Seidel, Jan Hüther, Frank Pistrosch, Heike Martin, Jens Schewe, Thomas Stehr, Frank Meistring, Alexander Paliege, Daniel Schneider, Ingolf BastAnne Steglich, Florian Gembardt, Friederike Kessel, Hannah Kröger, Patrick Arndt, Jan Sradnick, Kerstin Frank, Sarah Skrzypczyk, Moritz Anft, Anna Klimova, René Mauer, Ingo Roeder, Torsten Tonn, Nina Babel, Christian Hugo

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: SARS-CoV-2mRNA vaccination related seroconversion rates are reduced in dialysis and kidney transplant patients. Methods: We evaluated nine months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 880 participants including healthy medical personnel (125-MP), dialysis patients (595-DP), kidney transplant recipients (111-KTR), and apheresis patients (49-AP) with positive seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Nine months after first vaccination, receptor binding domain (RBD) antibodies were still positive in 90 % of MP, 86 % of AP, but only 55 %/48 % of DP/KTR, respectively. Seroconversion remained positive in 100 % of AP and 99·2 % of MP, but 86 %/81 % of DP/KTR, respectively. Compared to MP, DP but not KTR or AP were at risk for a strong RBD decline, while KTR kept lowest RBD values over time. By multivariate analysis, BNT162b2mRNA versus 1273-mRNA vaccine type was an independent risk factor for a strong decline of RBD antibodies. Within the DP group, only time on dialysis was another (inverse) risk factor for the DP group. Compared to humoral immunity, T-cell immunity decline was less prominent. Interpretation: While seroconverted KTR reach lowest RBD values over time, DP are at specific risk for a strong decline of RBD antibodies after successful SARS-CoV-2mRNA vaccination, which also depends on the vaccine type being used. Therefore, booster vaccinations for DP should be considered earlier compared to normal population.

Original language	English (US)
Pages (from-to)	120-128
Number of pages	9
Journal	Vaccine
Volume	42
Issue number	2
DOIs	https://doi.org/10.1016/j.vaccine.2023.12.034
State	Published - Jan 12 2024
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023

Keywords

BNT162B2
COVID-19
Clinical decision-making
Dialysis patients
Epidemiology
Guidelines
Humoral and cellular immune response
Immunity fading
Kidney transplant recipients
Medical personnel
SARS-CoV-2 vaccination
mRNA-1273

PubMed: MeSH publication types

Observational Study
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.vaccine.2023.12.034

Find It

Find It at U of M Libraries

Cite this

Stumpf, J., Anders, L., Siepmann, T., Schwöbel, J., Karger, C., Lindner, T., Faulhaber-Walter, R., Langer, T., Escher, K., Anding-Rost, K., Seidel, H., Hüther, J., Pistrosch, F., Martin, H., Schewe, J., Stehr, T., Meistring, F., Paliege, A., Schneider, D., ... Hugo, C. (2024). 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients. Vaccine, 42(2), 120-128. https://doi.org/10.1016/j.vaccine.2023.12.034

Stumpf, J, Anders, L, Siepmann, T, Schwöbel, J, Karger, C, Lindner, T, Faulhaber-Walter, R, Langer, T, Escher, K, Anding-Rost, K, Seidel, H, Hüther, J, Pistrosch, F, Martin, H, Schewe, J, Stehr, T, Meistring, F, Paliege, A, Schneider, D, Bast, I, Steglich, A, Gembardt, F, Kessel, F, Kröger, H, Arndt, P, Sradnick, J, Frank, K, Skrzypczyk, S, Anft, M, Klimova, A, Mauer, R, Roeder, I, Tonn, T, Babel, N & Hugo, C 2024, '9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients', Vaccine, vol. 42, no. 2, pp. 120-128. https://doi.org/10.1016/j.vaccine.2023.12.034

@article{f981fdb380b74530ba0de7d2d0c513c9,

title = "9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients",

abstract = "Background: SARS-CoV-2mRNA vaccination related seroconversion rates are reduced in dialysis and kidney transplant patients. Methods: We evaluated nine months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 880 participants including healthy medical personnel (125-MP), dialysis patients (595-DP), kidney transplant recipients (111-KTR), and apheresis patients (49-AP) with positive seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Nine months after first vaccination, receptor binding domain (RBD) antibodies were still positive in 90 % of MP, 86 % of AP, but only 55 %/48 % of DP/KTR, respectively. Seroconversion remained positive in 100 % of AP and 99·2 % of MP, but 86 %/81 % of DP/KTR, respectively. Compared to MP, DP but not KTR or AP were at risk for a strong RBD decline, while KTR kept lowest RBD values over time. By multivariate analysis, BNT162b2mRNA versus 1273-mRNA vaccine type was an independent risk factor for a strong decline of RBD antibodies. Within the DP group, only time on dialysis was another (inverse) risk factor for the DP group. Compared to humoral immunity, T-cell immunity decline was less prominent. Interpretation: While seroconverted KTR reach lowest RBD values over time, DP are at specific risk for a strong decline of RBD antibodies after successful SARS-CoV-2mRNA vaccination, which also depends on the vaccine type being used. Therefore, booster vaccinations for DP should be considered earlier compared to normal population.",

keywords = "BNT162B2, COVID-19, Clinical decision-making, Dialysis patients, Epidemiology, Guidelines, Humoral and cellular immune response, Immunity fading, Kidney transplant recipients, Medical personnel, SARS-CoV-2 vaccination, mRNA-1273",

author = "Julian Stumpf and Leona Anders and Torsten Siepmann and J{\"o}rg Schw{\"o}bel and Claudia Karger and Tom Lindner and Robert Faulhaber-Walter and Torsten Langer and Katja Escher and Kirsten Anding-Rost and Harald Seidel and Jan H{\"u}ther and Frank Pistrosch and Heike Martin and Jens Schewe and Thomas Stehr and Frank Meistring and Alexander Paliege and Daniel Schneider and Ingolf Bast and Anne Steglich and Florian Gembardt and Friederike Kessel and Hannah Kr{\"o}ger and Patrick Arndt and Jan Sradnick and Kerstin Frank and Sarah Skrzypczyk and Moritz Anft and Anna Klimova and Ren{\'e} Mauer and Ingo Roeder and Torsten Tonn and Nina Babel and Christian Hugo",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = jan,

day = "12",

doi = "10.1016/j.vaccine.2023.12.034",

language = "English (US)",

volume = "42",

pages = "120--128",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients

AU - Stumpf, Julian

AU - Anders, Leona

AU - Siepmann, Torsten

AU - Schwöbel, Jörg

AU - Karger, Claudia

AU - Lindner, Tom

AU - Faulhaber-Walter, Robert

AU - Langer, Torsten

AU - Escher, Katja

AU - Anding-Rost, Kirsten

AU - Seidel, Harald

AU - Hüther, Jan

AU - Pistrosch, Frank

AU - Martin, Heike

AU - Schewe, Jens

AU - Stehr, Thomas

AU - Meistring, Frank

AU - Paliege, Alexander

AU - Schneider, Daniel

AU - Bast, Ingolf

AU - Steglich, Anne

AU - Gembardt, Florian

AU - Kessel, Friederike

AU - Kröger, Hannah

AU - Arndt, Patrick

AU - Sradnick, Jan

AU - Frank, Kerstin

AU - Skrzypczyk, Sarah

AU - Anft, Moritz

AU - Klimova, Anna

AU - Mauer, René

AU - Roeder, Ingo

AU - Tonn, Torsten

AU - Babel, Nina

AU - Hugo, Christian

PY - 2024/1/12

Y1 - 2024/1/12

N2 - Background: SARS-CoV-2mRNA vaccination related seroconversion rates are reduced in dialysis and kidney transplant patients. Methods: We evaluated nine months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 880 participants including healthy medical personnel (125-MP), dialysis patients (595-DP), kidney transplant recipients (111-KTR), and apheresis patients (49-AP) with positive seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Nine months after first vaccination, receptor binding domain (RBD) antibodies were still positive in 90 % of MP, 86 % of AP, but only 55 %/48 % of DP/KTR, respectively. Seroconversion remained positive in 100 % of AP and 99·2 % of MP, but 86 %/81 % of DP/KTR, respectively. Compared to MP, DP but not KTR or AP were at risk for a strong RBD decline, while KTR kept lowest RBD values over time. By multivariate analysis, BNT162b2mRNA versus 1273-mRNA vaccine type was an independent risk factor for a strong decline of RBD antibodies. Within the DP group, only time on dialysis was another (inverse) risk factor for the DP group. Compared to humoral immunity, T-cell immunity decline was less prominent. Interpretation: While seroconverted KTR reach lowest RBD values over time, DP are at specific risk for a strong decline of RBD antibodies after successful SARS-CoV-2mRNA vaccination, which also depends on the vaccine type being used. Therefore, booster vaccinations for DP should be considered earlier compared to normal population.

AB - Background: SARS-CoV-2mRNA vaccination related seroconversion rates are reduced in dialysis and kidney transplant patients. Methods: We evaluated nine months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 880 participants including healthy medical personnel (125-MP), dialysis patients (595-DP), kidney transplant recipients (111-KTR), and apheresis patients (49-AP) with positive seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Nine months after first vaccination, receptor binding domain (RBD) antibodies were still positive in 90 % of MP, 86 % of AP, but only 55 %/48 % of DP/KTR, respectively. Seroconversion remained positive in 100 % of AP and 99·2 % of MP, but 86 %/81 % of DP/KTR, respectively. Compared to MP, DP but not KTR or AP were at risk for a strong RBD decline, while KTR kept lowest RBD values over time. By multivariate analysis, BNT162b2mRNA versus 1273-mRNA vaccine type was an independent risk factor for a strong decline of RBD antibodies. Within the DP group, only time on dialysis was another (inverse) risk factor for the DP group. Compared to humoral immunity, T-cell immunity decline was less prominent. Interpretation: While seroconverted KTR reach lowest RBD values over time, DP are at specific risk for a strong decline of RBD antibodies after successful SARS-CoV-2mRNA vaccination, which also depends on the vaccine type being used. Therefore, booster vaccinations for DP should be considered earlier compared to normal population.

KW - BNT162B2

KW - COVID-19

KW - Clinical decision-making

KW - Dialysis patients

KW - Epidemiology

KW - Guidelines

KW - Humoral and cellular immune response

KW - Immunity fading

KW - Kidney transplant recipients

KW - Medical personnel

KW - SARS-CoV-2 vaccination

KW - mRNA-1273

UR - http://www.scopus.com/inward/record.url?scp=85180342869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85180342869&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2023.12.034

DO - 10.1016/j.vaccine.2023.12.034

M3 - Article

C2 - 38114410

AN - SCOPUS:85180342869

SN - 0264-410X

VL - 42

SP - 120

EP - 128

JO - Vaccine

JF - Vaccine

IS - 2

ER -

9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this